These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28621112)

  • 1. Increased Immunogenicity and Protective Efficacy of a
    Ryu JI; Wui SR; Ko A; Lee YJ; Do H; Kim HJ; Rhee IM; Park SA; Kim KS; Cho YJ; Lee NG
    J Microbiol Biotechnol; 2017 Aug; 27(8):1539-1548. PubMed ID: 28621112
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia.
    Hamaoka S; Naito Y; Katoh H; Shimizu M; Kinoshita M; Akiyama K; Kainuma A; Moriyama K; Ishii KJ; Sawa T
    Microbiol Immunol; 2017 Feb; 61(2):64-74. PubMed ID: 28370521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intradermal vaccination with a Pseudomonas aeruginosa vaccine adjuvanted with a mutant bacterial ADP-ribosylating enterotoxin protects against acute pneumonia.
    Baker SM; Pociask D; Clements JD; McLachlan JB; Morici LA
    Vaccine; 2019 Feb; 37(6):808-816. PubMed ID: 30638799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
    Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia.
    Naito Y; Hamaoka S; Kinoshita M; Kainuma A; Shimizu M; Katoh H; Moriyama K; Ishii KJ; Sawa T
    Microbiol Immunol; 2018 Dec; 62(12):774-785. PubMed ID: 30378708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological evaluation of an alginate-based conjugate as a vaccine candidate against Pseudomonas aeruginosa.
    Farjah A; Owlia P; Siadat SD; Mousavi SF; Ardestani MS; Mohammadpour HK
    APMIS; 2015 Feb; 123(2):175-83. PubMed ID: 25470757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A De-
    Ryu JI; Park SA; Wui SR; Ko A; Han JE; Choi JA; Song MK; Kim KS; Cho YJ; Lee NG
    Biomed Res Int; 2016; 2016():3713656. PubMed ID: 27891512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological evaluation of OMP-F of native Iranian Pseudomonas aeruginosa as a protective vaccine.
    Ahmadi H; Tabaraie B; Maleknia S; Pormirzagholi F; Nejati M; Hedayati MH
    J Infect Dev Ctries; 2012 Oct; 6(10):721-6. PubMed ID: 23103894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa.
    Zhang M; Sun C; Gu J; Yan X; Wang B; Cui Z; Sun X; Tong C; Feng X; Lei L; Han W
    Microbiol Immunol; 2015 Sep; 59(9):533-44. PubMed ID: 26249788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice From
    Sen-Kilic E; Blackwood CB; Boehm DT; Witt WT; Malkowski AC; Bevere JR; Wong TY; Hall JM; Bradford SD; Varney ME; Damron FH; Barbier M
    Front Immunol; 2019; 10():2497. PubMed ID: 31708925
    [No Abstract]   [Full Text] [Related]  

  • 11. Protective effect of pilin protein with alum+naloxone adjuvant against acute pulmonary Pseudomonas aeruginosa infection.
    Banadkoki AZ; Keshavarzmehr M; Afshar Z; Aleyasin N; Fatemi MJ; Behrouz B; Hashemi FB
    Biologicals; 2016 Sep; 44(5):367-73. PubMed ID: 27427517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.
    Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB
    J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous
    Liu C; Pan X; Xia B; Chen F; Jin Y; Bai F; Priebe G; Cheng Z; Jin S; Wu W
    Front Immunol; 2018; 9():1737. PubMed ID: 30093906
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
    Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ
    Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
    Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
    APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant N-terminal outer membrane porin (OprF) of Pseudomonas aeruginosa is a promising vaccine candidate against both P. aeruginosa and some strains of Acinetobacter baumannii.
    Bahey-El-Din M; Mohamed SA; Sheweita SA; Haroun M; Zaghloul TI
    Int J Med Microbiol; 2020 Apr; 310(3):151415. PubMed ID: 32156509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of Genomic Library and High-Throughput Screening of Pseudomonas aeruginosa Novel Antigens for Potential Vaccines.
    Xu W; Li L; Wen X; Liu Q; Liu Y; Wang X; Lei L; Chen Q; Liu L
    Biol Pharm Bull; 2020 Oct; 43(10):1469-1475. PubMed ID: 32779581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the Mechanistic Correlates of Protection Conferred by Whole-Cell Vaccination against Pseudomonas aeruginosa Acute Murine Pneumonia.
    Sen-Kilic E; Blackwood CB; Huckaby AB; Horspool AM; Weaver KL; Malkowski AC; Witt WT; Bevere JR; Damron FH; Barbier M
    Infect Immun; 2021 Jan; 89(2):. PubMed ID: 33199354
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.
    Weimer ET; Ervin SE; Wozniak DJ; Mizel SB
    Vaccine; 2009 Nov; 27(48):6762-9. PubMed ID: 19744586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.
    Kamei A; Coutinho-Sledge YS; Goldberg JB; Priebe GP; Pier GB
    Infect Immun; 2011 Mar; 79(3):1289-99. PubMed ID: 21149583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.